

Bibliography

BIBLIOGRAPHY

1. Sharma M, Gogoi N, Dhananjaya BL, Menon JC, Doley R. Geographical variation of Indian Russell's viper venom and neutralization of its coagulopathy by polyvalent antivenom. *Toxin Rev*, 33(1–2):7–15, 2014.
2. Sharma M, Das D, Iyer JK, Kini RM, Doley R. Unveiling the complexities of *Daboia russelii* venom, a medically important snake of India, by tandem mass spectrometry. *Toxicon*, 107:266–81, 2015.
3. Doley R, Kini RM. Protein complexes in snake venom. *Cell Mol Life Sci*, 66(17):2851–71, 2009.
4. Mackessy SP. Handbook of Venoms and Toxins of Reptiles [Internet]. Second edi. Mackessy SP, editor. Boca Raton, USA: CRC Press; 2021.
5. Mohamed Abd El-Aziz, Garcia Soares, Stockand. Snake Venoms in Drug Discovery: Valuable Therapeutic Tools for Life Saving. *Toxins (Basel)*, 11(10):564, 2019.
6. Gutiérrez JM, Calvete JJ, Habib AG, Harrison RA, Williams DJ, Warrell DA. Snakebite envenoming. *Nat Rev Dis Prim*, 3(1):17063, 2017.
7. Mehta S, Sashindran V. Clinical Features And Management Of Snake Bite. *Med J Armed Forces India*, 58(3):247–9, 2002.
8. Mackie I., Bull H. Normal haemostasis and its regulation. *Blood Rev*, 3(4):237–50, 1989.
9. Rojnuckarin P. Snake Venom and Hemostasis. In: Clinical Toxinology, Springer, Dordrecht; p. 1–202013.
10. van Herrewegen F, Meijers JCM, Peters M, van Ommen CH. Clinical practice. *Eur J Pediatr*, 171(2):207–14, 2012.
11. Lu Q, Clemetson JM, Clemetson KJ. Snake venoms and hemostasis. *J Thromb Haemost*, 3(8):1791–9, 2005.
12. McCleary RJR, Kini RM. Snake bites and hemostasis/thrombosis. *Thromb Res*, 132(6):642–6, 2013.
13. Zhang Y, Xiong YL, Bon C. An activator of blood coagulation factor X from the venom of *Bungarus fasciatus*. *Toxicon*, 33(10):1277–88, 1995.
14. Lee WH, Zhang Y, Wang WY, Xiong YL, Gao R. Isolation and properties of a blood coagulation factor X activator from the venom of king cobra (*Ophiophagus hannah*). *Toxicon*, 33(10):1263–76, 1995.
15. Tokunaga F, Nagasawa K, Tamura S, Miyata T, Iwanaga S, Kisiel W. The factor

- V-activating enzyme (RVV-V) from Russell's viper venom. Identification of isoproteins RVV-V alpha, -V beta, and -V gamma and their complete amino acid sequences. *J Biol Chem*, 263(33):17471–81, 1988.
16. Takeya H, Nishida S, Miyata T, Kawada S, Saisaka Y, Morita T, et al. Coagulation factor X activating enzyme from Russell's viper venom (RVV-X). A novel metalloproteinase with disintegrin (platelet aggregation inhibitor)-like and C-type lectin-like domains. *J Biol Chem*, 267(20):14109–17, 1992.
 17. Lindquist PA, Fujikawa K, Davie EW. Activation of bovine factor IX (Christmas factor) by factor XIa (activated plasma thromboplastin antecedent) and a protease from Russell's viper venom. *J Biol Chem*, 253(6):1902–9, 1978.
 18. Berger M, Pinto AFM, Guimarães JA. Purification and functional characterization of bothrojaractivase, a prothrombin-activating metalloproteinase isolated from Bothrops jararaca snake venom. *Toxicon*, 51(4):488–501, 2008.
 19. Loría GD, Rucavado A, Kamiguti AS, Theakston RDG, Fox JW, Alape A, et al. Characterization of “basparin A,” a prothrombin-activating metalloproteinase, from the venom of the snake Bothrops asper that inhibits platelet aggregation and induces defibrination and thrombosis. *Arch Biochem Biophys*, 418(1):13–24, 2003.
 20. Rao VS, Kini RM. Pseutarin C, a prothrombin activator from Pseudonaja textilis venom: its structural and functional similarity to mammalian coagulation factor Xa-Va complex. *Thromb Haemost*, 88(4):611–9, 2002.
 21. Joseph JS, Chung MC, Jeyaseelan K, Kini RM. Amino acid sequence of trocarin, a prothrombin activator from Tropidechis carinatus venom: its structural similarity to coagulation factor Xa. *Blood*, 94(2):621–31, 1999.
 22. Bell WR. Defibrinogenating enzymes. *Drugs*, 54 Suppl 3:18–30; discussion 30-1, 1997.
 23. Barnwal B, Jobichen C, Girish VM, Foo CS, Sivaraman J, Kini RM. Ringhalexin from Hemachatus haemachatus: A novel inhibitor of extrinsic tenase complex. *Sci Rep*, 6(1):25935, 2016.
 24. Banerjee Y, Mizuguchi J, Iwanaga S, Kini RM. Hemextin AB complex--a snake venom anticoagulant protein complex that inhibits factor VIIa activity. *Pathophysiol Haemost Thromb*, 34(4–5):184–7, 2005.
 25. Sakurai Y, Shima M, Matsumoto T, Takatsuka H, Nishiya K, Kasuda S, et al. Anticoagulant activity of M-LAO, L-amino acid oxidase purified from Agkistrodon halys blomhoffii, through selective inhibition of factor IX. *Biochim Biophys Acta*, 1649(1):51–7, 2003.
 26. Hall, J.E., & Guyton AC. Guyton and Hall textbook of medical physiology. 13th

- ed. Philadelphia: PA: Saunders Elsevier; 2011.
27. Drellich DA, Bray PF. The Traditional Role of Platelets in Hemostasis. In: The Non-Thrombotic Role of Platelets in Health and Disease, InTech; 2015.
 28. Zhou Y, Yasumoto A, Lei C, Huang CJ, Kobayashi H, Wu Y, et al. Intelligent classification of platelet aggregates by agonist type. *Elife*, 9 2020.
 29. Andrews RK, Berndt MC. Platelet physiology and thrombosis. *Thromb Res*, 114(5–6):447–53, 2004.
 30. Varga-Szabo D, Pleines I, Nieswandt B. Cell Adhesion Mechanisms in Platelets. *Arterioscler Thromb Vasc Biol*, 28(3):403–12, 2008.
 31. Jurk K, Kehrel BE. Platelets: Physiology and Biochemistry. *Semin Thromb Hemost*, 31(04):381–92, 2005.
 32. Heemskerk JWM, Kuijpers MJE, Munnix ICA, Siljander PRM. Platelet Collagen Receptors and Coagulation. A Characteristic Platelet Response as Possible Target for Antithrombotic Treatment. *Trends Cardiovasc Med*, 15(3):86–92, 2005.
 33. Nieswandt B, Schulte V, Bergmeier W, Mokhtari-Nejad R, Rackebrandt K, Cazenave JP, et al. Long-Term Antithrombotic Protection by in Vivo Depletion of Platelet Glycoprotein VI in Mice. *J Exp Med*, 193(4):459–70, 2001.
 34. Bevers EM, Comfurius P, Van Rijn JLML, Hemker HC. Generation of Prothrombin-Converting Activity and the Exposure of Phosphatidylserine at the Outer Surface of Platelets. *Eur J Biochem*, 122(2):429–36, 1982.
 35. Leger AJ, Covic L, Kuliopulos A. Protease-Activated Receptors in Cardiovascular Diseases. *Circulation*, 114(10):1070–7, 2006.
 36. Heuberger DM, Schuepbach RA. Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. *Thromb J*, 17(1):4, 2019.
 37. Gandhi PS, Chen Z, Appelbaum E, Zapata F, Di Cera E. Structural basis of thrombin-protease-activated receptor interactions. *IUBMB Life*, 63(6):375–82, 2011.
 38. Clemetson K, Lu Q, Clemetson J. Snake Venom Proteins Affecting Platelets and Their Applications to Anti-Thrombotic Research. *Curr Pharm Des*, 13(28):2887–92, 2007.
 39. Nishida S, Fujimura Y, Miura S, Yoshida E, Sugimoto M, Yoshioka A, et al. Purification and Characterization of Bothrombin, a Fibrinogen-Clotting Serine Protease from the Venom of Bothrops jararaca. *Biochemistry*, 33(7):1843–9, 1994.

40. Usami Y, Fujimura Y, Suzuki M, Ozeki Y, Nishio K, Fukui H, et al. Primary structure of two-chain botrocetin, a von Willebrand factor modulator purified from the venom of Bothrops jararaca. *Proc Natl Acad Sci*, 90(3):928–32, 1993.
41. Li R. The Glycoprotein Ib-IX-V Complex. In: *Platelets*, Elsevier; p. 193–2112019.
42. Andrews RK, Booth WJ, Gorman JJ, Castaldi PA, Berndt MC. Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib-IX complex. *Biochemistry*, 28(21):8317–26, 1989.
43. Hamako J, Matsui T, Suzuki M, Ito M, Makita K, Fujimura Y, et al. Purification and Characterization of Bitiscetin, a Novel von Willebrand Factor Modulator Protein from Bitis arietans Snake Venom. *Biochem Biophys Res Commun*, 226(1):273–9, 1996.
44. Fuly AL, Soares AM, Marcussi S, Giglio JR, Guimarães JA. Signal transduction pathways involved in the platelet aggregation induced by a D-49 phospholipase A2 isolated from Bothrops jararacussu snake venom. *Biochimie*, 86(9–10):731–9, 2004.
45. Blenner MA, Dong X, Springer TA. Structural Basis of Regulation of von Willebrand Factor Binding to Glycoprotein Ib. *J Biol Chem*, 289(9):5565–79, 2014.
46. Maita N, Nishio K, Nishimoto E, Matsui T, Shikamoto Y, Morita T, et al. Crystal Structure of von Willebrand Factor A1 Domain Complexed with Snake Venom, Bitiscetin. *J Biol Chem*, 278(39):37777–81, 2003.
47. Horii K, Okuda D, Morita T, Mizuno H. Crystal structure of EMS16 in complex with the integrin alpha2-I domain. *J Mol Biol*, 341(2):519–27, 2004.
48. Eble JA, Beermann B, Hinz HJ, Schmidt-Hederich A. alpha 2beta 1 integrin is not recognized by rhodocytin but is the specific, high affinity target of rhodocetin, an RGD-independent disintegrin and potent inhibitor of cell adhesion to collagen. *J Biol Chem*, 276(15):12274–84, 2001.
49. Zingali RB, Jandrot-Perrus M, Guillin MC, Bon C. Bothrojaracin, a new thrombin inhibitor isolated from Bothrops jararaca venom: Characterization and mechanism of thrombin inhibition. *Biochemistry*, 32(40):10794–802, 1993.
50. Arocas V, Zingali RB, Guillin MC, Bon C, Jandrot-Perrus M. Bothrojaracin: A Potent Two-Site-Directed Thrombin Inhibitor. *Biochemistry*, 35(28):9083–9, 1996.
51. Sanchez EF, Richardson M, Gremski LH, Veiga SS, Yarleque A, Niland S, et al. A novel fibrinolytic metalloproteinase, barnettlysin-I from Bothrops barnetti

- (barnett's pitviper) snake venom with anti-platelet properties. *Biochim Biophys Acta - Gen Subj*, 1860(3):542–56, 2016.
52. Mendis S, Puska P, Norrving B, World Health Organization., World Heart Federation., World Stroke Organization. Global atlas on cardiovascular disease prevention and control. World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization; 155 p.2011.
 53. Nason E. An overview of cardiovascular disease and research. [Internet]. Santa Monica, CA; 2008. (RAND Corporation).
 54. Ghantous CM, Kamareddine L, Farhat R, Zouein FA, Mondello S, Kobeissy F, et al. Advances in Cardiovascular Biomarker Discovery. *Biomedicines*, 8(12):552, 2020.
 55. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. *J Am Coll Cardiol*, 76(25):2982–3021, 2020.
 56. Mehta NJ, Khan IA. Cardiology's 10 greatest discoveries of the 20th century. *Texas Hear Inst J*, 29(3):164–71, 2002.
 57. Xu M, Zhang K, Song J. Targeted Therapy in Cardiovascular Disease: A Precision Therapy Era. *Front Pharmacol*, 12 2021.
 58. Morange PE, Bickel C, Nicaud V, Schnabel R, Rupprecht HJ, Peetz D, et al. Haemostatic Factors and the Risk of Cardiovascular Death in Patients With Coronary Artery Disease. *Arterioscler Thromb Vasc Biol*, 26(12):2793–9, 2006.
 59. Gregg D, Goldschmidt-Clermont PJ. Platelets and Cardiovascular Disease. *Circulation*, 108(13) 2003.
 60. Ross R. Atherosclerosis — An Inflammatory Disease. Epstein FH, editor. *N Engl J Med*, 340(2):115–26, 1999.
 61. Gelchu T, Abdela J. Drug therapy problems among patients with cardiovascular disease admitted to the medical ward and had a follow-up at the ambulatory clinic of Hiwot Fana Specialized University Hospital: The case of a tertiary hospital in eastern Ethiopia. *SAGE Open Med*, 7:205031211986040, 2019.
 62. Averin AS, Utkin YN. Cardiovascular Effects of Snake Toxins: Cardiotoxicity and Cardioprotection. *Acta Naturae*, 13(3):4–14, 2021.
 63. Vonk FJ, Jackson K, Doley R, Madaras F, Mirtschin PJ, Vidal N. Snake venom: From fieldwork to the clinic. *BioEssays*, 33(4):269–79, 2011.
 64. Oliveira AL, Viegas MF, da Silva SL, Soares AM, Ramos MJ, Fernandes PA. The chemistry of snake venom and its medicinal potential. *Nat Rev Chem*, 6(7):451–69, 2022.

65. Atkinson A., Robertson JI. Captopril in the treatment of clinical hypertension and cardiac failure. *Lancet*, 314(8147):836–9, 1979.
66. Crow JM. Venomous drugs: Captopril. *New Sci*, 214(2863):35, 2012.
67. Koh CY, Kini RM. From snake venom toxins to therapeutics – Cardiovascular examples. *Toxicon*, 59(4):497–506, 2012.
68. Gan ZR, Gould RJ, Jacobs JW, Friedman PA, Polokoff MA. Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, *Echis carinatus*. *J Biol Chem*, 263(36):19827–32, 1988.
69. Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM, et al. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of *Sistrurus m. barbouri*. *J Biol Chem*, 266(15):9359–62, 1991.
70. Swedberg K, Kjeksus J. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *Am J Cardiol*, 62(2):60A-66A, 1988.
71. Tang L, Tang X, Yang Q. The Application of Tirofiban in the Endovascular Treatment of Acute Ischemic Stroke: A Meta-Analysis. *Cerebrovasc Dis*, 50(2):121–31, 2021.
72. Scarborough RM. Development of eptifibatide. *Am Heart J*, 138(6):1093–104, 1999.
73. Ding J, Zhou D, Hu Y, Elmadhoun O, Pan L, Ya J, et al. The efficacy and safety of Batroxobin in combination with anticoagulation on cerebral venous sinus thrombosis. *J Thromb Thrombolysis*, 46(3):371–8, 2018.
74. Guo Y, Zuo Y fang, Wang Q zhang, Tang B shan, Li F kang, Sun Y. Meta-analysis of defibrase in treatment of acute cerebral infarction. *Chin Med J (Engl)*, 119(8):662–8, 2006.
75. Lei X, Reheman A, Hou Y, Zhou H, Wang Y, Marshall A, et al. Anfibatide, a novel GPIIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. *Thromb Haemost*, 111(02):279–89, 2014.
76. Kawakami R, Lee CYW, Scott C, Bailey KR, Schirger JA, Chen HH, et al. A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure. *Clin Pharmacol Ther*, 104(3):546–52, 2018.
77. Moll S, Kenyon P, Bertoli L, De Maio J, Homesley H, Deitcher SR. Phase II Trial of Alfimeprase, a Novel-Acting Fibrin Degradation Agent, for Occluded Central Venous Access Devices. *J Clin Oncol*, 24(19):3056–60, 2006.

78. Ho SJ, Brighton TA. Ximelagatran, direct thrombin inhibitor, oral anticoagulants, thromboprophylaxis. *Vasc Health Risk Manag*, 2(1):49–58, 2006.
79. Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. *Thromb Res*, 123(3):488–97, 2009.
80. Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. *Lancet*, 368(9550):1871–8, 2006.
81. Warrell DA. Snake venoms in science and clinical medicine 1. Russell’s viper: biology, venom and treatment of bites. *Trans R Soc Trop Med Hyg*, 83(6):732–40, 1989.
82. Whitaker R, Captain A. Snakes of India: The Field Guide. Chennai: Draco Books; 2004.
83. Ahsan MF, Saeed MA. Russell’s Viper (*Daboia Russelii*) in Bangladesh: Its Boom and Threat to Human Life. *J Asiat Soc Bangladesh, Sci*, 44(1):15–22, 2018.
84. Guidelines for the management of snakebites. 2016.
85. Kalita B, Mackessy SP, Mukherjee AK. Proteomic analysis reveals geographic variation in venom composition of Russell’s Viper in the Indian subcontinent: implications for clinical manifestations post-envenomation and antivenom treatment. *Expert Rev Proteomics*, 15(10):837–49, 2018.
86. Daltry JC, Wüster W, Thorpe RS. Diet and snake venom evolution. *Nature*, 379(6565):537–40, 1996.
87. Pla D, Sanz L, Quesada-Bernat S, Villalta M, Baal J, Chowdhury MAW, et al. Phylovenomics of *Daboia russelii* across the Indian subcontinent. Bioactivities and comparative in vivo neutralization and in vitro third-generation antivenomics of antivenoms against venoms from India, Bangladesh and Sri Lanka. *J Proteomics*, 207:103443, 2019.
88. Kalita B, Singh S, Patra A, Mukherjee AK. Quantitative proteomic analysis and antivenom study revealing that neurotoxic phospholipase A2 enzymes, the major toxin class of Russell’s viper venom from southern India, shows the least immuno-recognition and neutralization by commercial polyvalent anti. *Int J Biol Macromol*, 118:375–85, 2018.
89. Giri S, Teye SJ, Shyam R, Saikia B, Jangid R, Yasmin R, et al. Recurrent neurotoxicity in *Naja kaouthia* envenomation: A case report from Assam, India. *Toxicon*, 222:106990, 2023.

90. Sharma M. Proteomics of Indian Daboia russelii venom (Irula) and characterization of a major protein. Tezpur University; 2016.
91. Sharma M, Iyer JK, Shih N, Majumder M, Mattaparthi VSK, Mukhopadhyay R, et al. Daboxin P, a Major Phospholipase A2 Enzyme from the Indian Daboia russelii russelii Venom Targets Factor X and Factor Xa for Its Anticoagulant Activity. Permyakov EA, editor. *PLoS One*, 11(4):e0153770, 2016.
92. Chandra V, Kaur P, Srinivasan A, Singh TP. Three-dimensional structure of a presynaptic neurotoxic phospholipase A2 from Daboia russelli pulchella at 2.4 Å resolution 1 Edited by D. Rees. *J Mol Biol*, 296(4):1117–26, 2000.
93. Saikia D, Thakur R, Mukherjee AK. An acidic phospholipase A(2) (RVVA-PLA(2)-I) purified from Daboia russelli venom exerts its anticoagulant activity by enzymatic hydrolysis of plasma phospholipids and by non-enzymatic inhibition of factor Xa in a phospholipids/Ca(2+) independent manner. *Toxicon*, 57(6):841–50, 2011.
94. Kasturi S, Gowda TV. Purification and characterization of a major phospholipase A2 from Russell's viper (*Vipera russelli*) venom. *Toxicon*, 27(2):229–37, 1989.
95. Saikia D, Majumdar S, Mukherjee AK. Mechanism of in vivo anticoagulant and haemolytic activity by a neutral phospholipase A2 purified from Daboia russelii russelii venom: Correlation with clinical manifestations in Russell's Viper envenomed patients. *Toxicon*, 76:291–300, 2013.
96. Chakraborty AK, Hall RH, Ghose AC. Purification and characterization of a potent hemolytic toxin with phospholipase A2 activity from the venom of Indian Russell's viper. *Mol Cell Biochem*, 237(1–2):95–102, 2002.
97. Chen HS, Tsai HY, Wang YM, Tsai IH. P-III hemorrhagic metalloproteinases from Russell's viper venom: Cloning, characterization, phylogenetic and functional site analyses. *Biochimie*, 90(10):1486–98, 2008.
98. Kole L, Chakrabarty D, Datta K, Bhattacharyya D. Purification and characterization of an organ specific haemorrhagic toxin from *Vipera russelli russelli* (Russell's viper) venom. *Indian J Biochem Biophys*, 37(2):114–20, 2000.
99. Chakrabarty D, Bhattacharyya D, Sarkar HS, Lahiri SC. Purification and partial characterization of a haemorrhagin (VRH-1) from *Vipera russelli russelli* venom. *Toxicon*, 31(12):1601–14, 1993.
100. Chakrabarty D, Datta K, Gomes A, Bhattacharyya D. Haemorrhagic protein of Russell's viper venom with fibrinolytic and esterolytic activities. *Toxicon*, 38(11):1475–90, 2000.
101. Mukherjee AK. Characterization of a novel pro-coagulant metalloprotease (RVBCMP) possessing alpha-fibrinogenase and tissue haemorrhagic activity

- from venom of *Daboia russelii russelii* (Russell's viper): evidence of distinct coagulant and haemorrhagic sites in RVBCMP. *Toxicon*, 51(5):923–33, 2008.
102. Thakur R, Chattopadhyay P, Ghosh SS, Mukherjee AK. Elucidation of procoagulant mechanism and pathophysiological significance of a new prothrombin activating metalloprotease purified from *Daboia russelii russelii* venom. *Toxicon*, 100:1–12, 2015.
 103. Thakur R, Kumar A, Bose B, Panda D, Saikia D, Chattopadhyay P, et al. A new peptide (Ruviprase) purified from the venom of *Daboia russelii russelii* shows potent anticoagulant activity via non-enzymatic inhibition of thrombin and factor Xa. *Biochimie*, 105:149–58, 2014.
 104. Laemmli UK. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4. *Nature*, 227(5259):680–5, 1970.
 105. Thakur S, Blotra A, Vasudevan K, Malhotra A, Lalremsanga HT, Santra V, et al. Proteome Decomplexation of *Trimeresurus erythrurus* Venom from Mizoram, India. *J Proteome Res*, 22(1):215–25, 2023.
 106. Babele P, Verma S, Kumar RB, Bhagyawant SS, Kamboj DV, Alam SI. Elucidation of protein biomarkers in plasma and urine for epsilon toxin exposure in mouse model. *Anaerobe*, 59:76–91, 2019.
 107. Babele P, Kumar RB, Rajoria S, Rashid F, Malakar D, Bhagyawant SS, et al. Putative serum protein biomarkers for epsilon toxin exposure in mouse model using LC-MS/MS analysis. *Anaerobe*, 63:102209, 2020.
 108. Tamura K, Stecher G, Kumar S. MEGA11: Molecular Evolutionary Genetics Analysis Version 11. Battistuzzi FU, editor. *Mol Biol Evol*, 38(7):3022–7, 2021.
 109. Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. *J Lab Clin Med*, 41(4):637–47, 1953.
 110. Joubert FJ, Taljaard N. Purification, Some Properties and Amino-Acid Sequences of Two Phospholipases A (CM-II and CM-III) from *Naja naja kaouthia* Venom. *Eur J Biochem*, 112(3):493–9, 2005.
 111. Doley R, Mukherjee AK. Purification and characterization of an anticoagulant phospholipase A2 from Indian monocled cobra (*Naja kaouthia*) venom. *Toxicon*, 41(1):81–91, 2003.
 112. Ouyang C, Teng CM. Fibrinogenolytic enzymes of *Trimeresurus mucrosquamatus* venom. *Biochim Biophys Acta*, 420(2):298–308, 1976.
 113. Mukherjee AK, Ghosal SK, Maity CR. Some biochemical properties of Russell's viper (*Daboia russelii*) venom from Eastern India: correlation with clinico-pathological manifestation in Russell's viper bite. *Toxicon*, 38(2):163–75, 2000.

114. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem*, 193(1):265–75, 1951.
115. Born GVR, Cross MJ. The aggregation of blood platelets. *J Physiol*, 168(1):178–95, 1963.
116. AAT Bioquest, Inc. [Internet]. Quest Graph™ LC50 Calculator; 2021.
117. Chan M V., Armstrong PC, Warner TD. 96-well plate-based aggregometry. *Platelets*, 29(7):650–5, 2018.
118. Ishii H, Umeda F, Hashimoto T, Nawata H. Increased intracellular calcium mobilization in platelets from patients with Type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia*, 34(5):332–6, 1991.
119. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca²⁺ indicators with greatly improved fluorescence properties. *J Biol Chem*, 260(6):3440–50, 1985.
120. Ohlmann P, Hechler B, Cazenave JP, Gachet C. Measurement and Manipulation of [Ca²⁺]_i in Suspensions of Platelets and Cell Cultures. In: *Platelets and Megakaryocytes*, New Jersey: Humana Press; p. 229–502004.
121. Maduwage K, Hodgson WC, Konstantakopoulos N, O’Leary MA, Gawarammana I, Isbister GK. The in vitro toxicity of venoms from South Asian hump-nosed pit vipers (Viperidae: Hypnale). *J Venom Res*, 2:17–23, 2011.
122. Bateman A, Martin MJ, Orchard S, Magrane M, Agivetova R, Ahmad S, et al. UniProt: the universal protein knowledgebase in 2021. *Nucleic Acids Res*, 49(D1):D480–9, 2021.
123. Gandhi PS, Chen Z, Di Cera E. Crystal Structure of Thrombin Bound to the Uncleaved Extracellular Fragment of PAR1. *J Biol Chem*, 285(20):15393–8, 2010.
124. Desta IT, Porter KA, Xia B, Kozakov D, Vajda S. Performance and Its Limits in Rigid Body Protein-Protein Docking. *Structure*, 28(9):1071-1081.e3, 2020.
125. BIOVIA. Discovery Studio R2 software package. San Diego: Dassault Systemes; 2017.
126. Laskowski RA. PDBsum new things. *Nucleic Acids Res*, 37(Database):D355–9, 2009.
127. Deka A, Gogoi A, Das D, Purkayastha J, Doley R. Proteomics of Naja kaouthia venom from North East India and assessment of Indian polyvalent antivenom by third generation antivenomics. *J Proteomics*, 207:103463, 2019.
128. Kalita B, Patra A, Mukherjee AK. Unraveling the Proteome Composition and Immuno-profiling of Western India Russell’s Viper Venom for In-Depth Understanding of Its Pharmacological Properties, Clinical Manifestations, and

- Effective Antivenom Treatment. *J Proteome Res*, 16(2):583–98, 2017.
129. Kalita B, Patra A, Das A, Mukherjee AK. Proteomic Analysis and Immuno-Profiling of Eastern India Russell’s Viper (*Daboia russelii*) Venom: Correlation between RVV Composition and Clinical Manifestations Post RV Bite. *J Proteome Res*, 17(8):2819–33, 2018.
130. Mukherjee AK, Kalita B, Mackessy SP. A proteomic analysis of Pakistan *Daboia russelii russelii* venom and assessment of potency of Indian polyvalent and monovalent antivenom. *J Proteomics*, 144:73–86, 2016.
131. Senji Laxme RR, Khochare S, Attarde S, Kaur N, Jaikumar P, Shaikh NY, et al. The Middle Eastern Cousin: Comparative Venomics of *Daboia palaestinae* and *Daboia russelii*. *Toxins (Basel)*, 14(11):725, 2022.
132. Tan KY, Tan NH, Tan CH. Venom proteomics and antivenom neutralization for the Chinese eastern Russell’s viper, *Daboia siamensis* from Guangxi and Taiwan. *Sci Rep*, 8(1):8545, 2018.
133. Management of Snakebite, 2017 [Internet].
134. Aung-Khin M, Ma-Ma K, Zin T. Effects of Russell’s viper venom on blood coagulation, platelets and the fibrinolytic enzyme system. *Japanese J Med Sci Biol*, 30(2):101–8, 1977.
135. Than T, Hutton RA, Lwin M, Han KE, Soe S, Swe TN, et al. Haemostatic disturbances in patients bitten by Russell’s viper (*Vipera russelli siamensis*) in Burma. *Br J Haematol*, 69(4):513–20, 1988.
136. Du XY, Clemetson KJ. Snake venom l-amino acid oxidases. *Toxicon*, 40(6):659–65, 2002.
137. Clemetson KJ. Snaclecs (snake C-type lectins) that inhibit or activate platelets by binding to receptors. *Toxicon*, 56(7):1236–46, 2010.
138. Manjunatha Kini R. Excitement ahead: structure, function and mechanism of snake venom phospholipase A2 enzymes. *Toxicon*, 42(8):827–40, 2003.
139. Gopalan G, Thwin MM, Gopalakrishnakone P, Swaminathan K. Structural and pharmacological comparison of daboiatoxin from *Daboia russelli siamensis* with viperotoxin F and vipoxin from other vipers. *Acta Crystallogr D Biol Crystallogr*, 63(Pt 6):722–9, 2007.
140. Tsai IH, Tsai HY, Wang YM, Tun-Pe, Warrell DA. Venom phospholipases of Russell’s vipers from Myanmar and eastern India—Cloning, characterization and phylogeographic analysis. *Biochim Biophys Acta - Proteins Proteomics*, 1774(8):1020–8, 2007.
141. Carredano E, Westerlund B, Persson B, Saarinen M, Ramaswamy S, Eaker D, et

- al. The three-dimensional structures of two toxins from snake venom throw light on the anticoagulant and neurotoxic sites of phospholipase A2. *Toxicon*, 36(1):75–92, 1998.
142. Tan NH, Fung SY, Tan KY, Yap MKK, Gnanathasan CA, Tan CH. Functional venomics of the Sri Lankan Russell's viper (*Daboia russelii*) and its toxinological correlations. *J Proteomics*, 128:403–23, 2015.
143. Yang CC. Cobrotoxin: structure and function. *J Nat Toxins*, 8(2):221–33, 1999.
144. Maraganore JM, Merutka G, Cho W, Welches W, Kézdy FJ, Heinrikson RL. A new class of phospholipases A2 with lysine in place of aspartate 49. Functional consequences for calcium and substrate binding. *J Biol Chem*, 259(22):13839–43, 1984.
145. Polgar J, Magnenat EM, Peitsch MC, Wells TNC, Clemetson, Kenneth J. Asp-49 is not an absolute prerequisite for the enzymic activity of low-Mr phospholipases A2: purification, characterization and computer modelling of an enzymically active Ser-49 phospholipase A2, ecarpholin S, from the venom of *Echis carinatus sochureki*. *Biochem J*, 319(3):961–8, 1996.
146. Tsai IH, Wang YM, Chen YH, Tsai TS, Tu MC. Venom phospholipases A2 of bamboo viper (*Trimeresurus stejnegeri*): molecular characterization, geographic variations and evidence of multiple ancestries. *Biochem J*, 377(1):215–23, 2004.
147. Chijiwa T, Tokunaga E, Ikeda R, Terada K, Ogawa T, Oda-Ueda N, et al. Discovery of novel [Arg49]phospholipase A2 isozymes from *Protobothrops elegans* venom and regional evolution of *Crotalinae* snake venom phospholipase A2 isozymes in the southwestern islands of Japan and Taiwan. *Toxicon*, 48(6):672–82, 2006.
148. Maraganore JM, Heinrikson RL. The role of lysyl residues of phospholipases A2 in the formation of the catalytic complex. *Biochem Biophys Res Commun*, 131(1):129–38, 1985.
149. van den Bergh CJ, Slotboom AJ, Verheij HM, de Haas GH. The role of Asp-49 and other conserved amino acids in phospholipases A2 and their importance for enzymatic activity. *J Cell Biochem*, 39(4):379–90, 1989.
150. Castro-Amorim J, Novo de Oliveira A, Da Silva SL, Soares AM, Mukherjee AK, Ramos MJ, et al. Catalytically Active Snake Venom PLA 2 Enzymes: An Overview of Its Elusive Mechanisms of Reaction. *J Med Chem*, 66(8):5364–76, 2023.
151. Tsai IH, Lu PJ, Su JC. Two types of russell's viper revealed by variation in phospholipases A2 from venom of the subspecies. *Toxicon*, 34(1):99–109, 1996.
152. Calvete JJ, Juárez P, Sanz L. Snake venomics. Strategy and applications. *J Mass*

- Spectrom*, 42(11):1405–14, 2007.
153. Braud S. Snake venom proteins acting on hemostasis. *Biochimie*, 82(9–10):851–9, 2000.
 154. Zhong SR, Jin Y, Wu JB, Chen RQ, Jia YH, Wang WY, et al. Characterization and molecular cloning of dabocetin, a potent antiplatelet C-type lectin-like protein from *Daboia russelii siamensis* venom. *Toxicon*, 47(1):104–12, 2006.
 155. Zhong Shu-rong, Jin Yang, LI Dong-sheng, Wang Wan-yu XY liang. Molecular Cloning and Sequence Analyses of cDNAs Encoding Seven C-type Lectin-like Protein Subunits from *Daboia russelii siamensis*. *Zool Res*, 26(4):337–43, 2005.
 156. Nakayama D, Ben Ammar Y, Miyata T, Takeda S. Structural basis of coagulation factor V recognition for cleavage by RVV-V. *FEBS Lett*, 585(19):3020–5, 2011.
 157. Sukkapan P, Jia Y, Nuchprayoon I, Pérez JC. Phylogenetic analysis of serine proteases from Russell’s viper (*Daboia russelii siamensis*) and *Agkistrodon piscivorus leucostoma* venom. *Toxicon*, 58(2):168–78, 2011.
 158. Faisal T, Tan KY, Sim SM, Quraishi N, Tan NH, Tan CH. Proteomics, functional characterization and antivenom neutralization of the venom of Pakistani Russell’s viper (*Daboia russelii*) from the wild. *J Proteomics*, 183:1–13, 2018.
 159. Deka A, Sharma M, Mukhopadhyay R, Devi A, Doley R. Naja kaouthia venom protein, Nk-CRISP, upregulates inflammatory gene expression in human macrophages. *Int J Biol Macromol*, 160:602–11, 2020.
 160. Fujikawa K, Legaz ME, Davie EW. Bovine factor X 1 (Stuart factor). Mechanism of activation by a protein from Russell’s viper venom. *Biochemistry*, 11(26):4892–9, 1972.
 161. Yee KT, Tongsima S, Vasieva O, Ngamphiw C, Wilantho A, Wilkinson MC, et al. Analysis of snake venom metalloproteinases from Myanmar Russell’s viper transcriptome. *Toxicon*, 146:31–41, 2018.
 162. Trummal K, Tõnismägi K, Siigur E, Aaspõllu A, Lopp A, Sillat T, et al. A novel metalloprotease from *Vipera lebetina* venom induces human endothelial cell apoptosis. *Toxicon*, 46(1):46–61, 2005.
 163. Kaur S, Devi A, Saikia B, Doley R. Expression and characterization of Flavikunin: A Kunitz-type serine protease inhibitor identified in the venom gland cDNA library of *Bungarus flaviceps*. *J Biochem Mol Toxicol*, 33(4):e22273, 2019.
 164. Morjen M, Honoré S, Bazaa A, Abdelkafi-Koubaa Z, Ellafi A, Mabrouk K, et al. PIVL, a snake venom Kunitz-type serine protease inhibitor, inhibits in vitro and

- in vivo angiogenesis. *Microvasc Res*, 95:149–56, 2014.
165. Guo C teng, McClean S, Shaw C, Rao P fan, Ye M yu, Bjourson AJ. Trypsin and chymotrypsin inhibitor peptides from the venom of Chinese *Daboia russelii siamensis*. *Toxicon*, 63:154–64, 2013.
 166. Schweitz H, Heurteaux C, Bois P, Moinier D, Romey G, Lazdunski M. Calcicludine, a venom peptide of the Kunitz-type protease inhibitor family, is a potent blocker of high-threshold Ca²⁺ channels with a high affinity for L-type channels in cerebellar granule neurons. *Proc Natl Acad Sci U S A*, 91(3):878–82, 1994.
 167. Guo CT, McClean S, Shaw C, Rao PF, Ye MY, Bjourson AJ. Purification, characterization and molecular cloning of chymotrypsin inhibitor peptides from the venom of Burmese *Daboia russelii siamensis*. *Peptides*, 43:126–32, 2013.
 168. Ferrara N, Gerber HP. The Role of Vascular Endothelial Growth Factor in Angiogenesis. *Acta Haematol*, 106(4):148–56, 2001.
 169. Yamazaki Y, Takani K, Atoda H, Morita T. Snake Venom Vascular Endothelial Growth Factors (VEGFs) Exhibit Potent Activity through Their Specific Recognition of KDR (VEGF Receptor 2). *J Biol Chem*, 278(52):51985–8, 2003.
 170. Calvete JJ. Structure-function correlations of snake venom disintegrins. *Curr Pharm Des*, 11(7):829–35, 2005.
 171. Niewiarowski S, McLane MA, Kloczewiak M, Stewart GJ. Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors. *Semin Hematol*, 31(4):289–300, 1994.
 172. Williams JA. Disintegrins: RGD-containing proteins which inhibit cell/matrix interactions (adhesion) and cell/cell interactions (aggregation) via the integrin receptors. *Pathol Biol (Paris)*, 40(8):813–21, 1992.
 173. Li AK, Koroly MJ, Schattenkerk ME, Malt RA, Young M. Nerve growth factor: acceleration of the rate of wound healing in mice. *Proc Natl Acad Sci*, 77(7):4379–81, 1980.
 174. Otten U, Baumann JB, Girard J. Nerve growth factor induces plasma extravasation in rat skin. *Eur J Pharmacol*, 106(1):199–201, 1984.
 175. Sajevic T, Leonardi A, Križaj I. Haemostatically active proteins in snake venoms. *Toxicon*, 57(5):627–45, 2011.
 176. Chen HS, Wang YM, Huang WT, Huang KF, Tsai IH. Cloning, characterization and mutagenesis of Russell's viper venom L-amino acid oxidase: Insights into its catalytic mechanism. *Biochimie*, 94(2):335–44, 2012.
 177. Wang YM, Huang KF, Tsai IH. Snake venom glutaminyl cyclases: Purification,

- cloning, kinetic study, recombinant expression, and comparison with the human enzyme. *Toxicon*, 86:40–50, 2014.
178. Thorpe RS, Pook CE, Malhotra A. Phylogeography of the Russell's viper (*Daboia russelii*) complex in relation to variation in the colour pattern and symptoms of envenoming. *Herpetol J*, :209–18, 2007.
179. Warrell DA. Snake bite. *Lancet*, 375:77–88, 2010.
180. Suraweera W, Warrell D, Whitaker R, Menon G, Rodrigues R, Fu SH, et al. Trends in snakebite deaths in India from 2000 to 2019 in a nationally representative mortality study. *Elife*, 9 2020.
181. Baumgartner HR, Haudenschild C. Adhesion of platelets to subendothelium. *Ann N Y Acad Sci*, 201(1):22–36, 1972.
182. Roberts DE, McNicol A, Bose R. Mechanism of Collagen Activation in Human Platelets. *J Biol Chem*, 279(19):19421–30, 2004.
183. Sangkuhl K, Shuldiner AR, Klein TE, Altman RB. Platelet aggregation pathway. *Pharmacogenet Genomics*, 21(8):516–21, 2011.
184. Yun SH, Sim EH, Goh RY, Park JI, Han JY. Platelet Activation: The Mechanisms and Potential Biomarkers. *Biomed Res Int*, 2016:1–5, 2016.
185. Murugappa S, Kunapuli SP. The role of ADP receptors in platelet function. *Front Biosci*, 11:1977–86, 2006.
186. Gachet C. ADP receptors of platelets and their inhibition. *Thromb Haemost*, 86(1):222–32, 2001.
187. Jennings L. Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. *Thromb Haemost*, 102(08):248–57, 2009.
188. Dong JF, Berndt MC, Schade A, McIntire L V., Andrews RK, López JA. Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions. *Blood*, 97(1):162–8, 2001.
189. Abildgaard U, Lie M, Ødegård OR. Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH). *Thromb Res*, 11(4):549–53, 1977.
190. Peng M, Lu W, Beviglia L, Niewiarowski S, Kirby EP. Echicetin: a snake venom protein that inhibits binding of von Willebrand factor and alboaggregins to platelet glycoprotein Ib. *Blood*, 81(9):2321–8, 1993.
191. Navdaev A, Clemetson JM, Polgar J, Kehrel BE, Glauner M, Magnenat E, et al. Aggretin, a heterodimeric C-type lectin from *Calloselasma rhodostoma* (Malayan

- pit viper), stimulates platelets by binding to $\alpha 2\beta 1$ integrin and glycoprotein Ib, activating Syk and phospholipase C γ 2, but does not involve the glycoprotein VI/Fc receptor γ c. *J Biol Chem*, 276(24):20882–9, 2001.
192. Du XY, Navdaev A, Clemetson JM, Magnenat E, Wells TN, Clemetson KJ. Bilinexin, a snake C-type lectin from Agkistrodon bilineatus venom agglutinates platelets via GPIb and alpha2beta1. *Thromb Haemost*, 86(5):1277–83, 2001.
193. Wong ESW, Belov K. Venom evolution through gene duplications. *Gene*, 496(1):1–7, 2012.
194. Mukherjee AK, Kalita B, Thakur R. Two Acidic, Anticoagulant PLA2 Isoenzymes Purified from the Venom of Monocled Cobra Naja kaouthia Exhibit Different Potency to Inhibit Thrombin and Factor Xa via Phospholipids Independent, Non-Enzymatic Mechanism. Lomonte B, editor. *PLoS One*, 9(8):e101334, 2014.
195. Vittet D, Mathieu MN, Launay JM, Chevillard C. Platelet receptor expression on three human megakaryoblast-like cell lines. *Exp Hematol*, 20(9):1129–34, 1992.
196. Horii K, Kahn ML, Herr AB. Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. *Blood*, 108(3):936–42, 2006.
197. Gurbel PA, Jeong YH, Tantry US. Vorapaxar: a novel protease-activated receptor-1 inhibitor. *Expert Opin Investig Drugs*, 20(10):1445–53, 2011.
198. Pan H, Boucher M, Kaunelis D. PAR-1 Antagonists: An Emerging Antiplatelet Drug Class [Internet]. CADTH Issues in Emerging Health Technologies. 2016.
199. Lin YC, Ko YC, Hung SC, Lin YT, Lee JH, Tsai JY, et al. Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog. *Arterioscler Thromb Vasc Biol*, 39(4):694–703, 2019.
200. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. The refined 1.9 Å crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. *EMBO J*, 8(11):3467–75, 1989.
201. Tanaka-Azevedo AM, Morais-Zani K, Torquato RJS, Tanaka AS. Thrombin Inhibitors from Different Animals. *J Biomed Biotechnol*, 2010:1–9, 2010.
202. Davie E, Kulman J. An Overview of the Structure and Function of Thrombin. *Semin Thromb Hemost*, 32(S 1):003–15, 2006.
203. Huntington JA. Molecular recognition mechanisms of thrombin. *J Thromb Haemost*, 3(8):1861–72, 2005.
204. Troisi R, Balasco N, Autiero I, Vitagliano L, Sica F. Exosite Binding in

- Thrombin: A Global Structural/Dynamic Overview of Complexes with Aptamers and Other Ligands. *Int J Mol Sci*, 22(19):10803, 2021.
205. Chahal G, Thorpe M, Hellman L. The Importance of Exosite Interactions for Substrate Cleavage by Human Thrombin. Cheng XW, editor. *PLoS One*, 10(6):e0129511, 2015.
206. Lane DA, Philippou H, Huntington JA. Directing thrombin. *Blood*, 106(8):2605–12, 2005.
207. Bah A, Chen Z, Bush-Pelc LA, Mathews FS, Di Cera E. Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4. *Proc Natl Acad Sci*, 104(28):11603–8, 2007.

List of publications

List of publications

- i. **R. Yasmin**, A. Blotra, A. Sahu, K. Vasudevan, M. A. Reza, R. Doley, “Proteome analysis of *Daboia russelii* venom from Rajshahi, Bangladesh.” (*In communication*)
- ii. **R. Yasmin**, S. Chanchal, M. Z. Ashraf and R. Doley, “Daboxin P, a phospholipase A₂ of Indian *Daboia russelii* venom, modulates thrombin-mediated platelet aggregation”, J.Biochem.Mol.Tox., Jul 2023, doi: 10.1002/jbt.23476.
- iii. R. Kashyap, P. Boro, **R. Yasmin**, J. Nath, D. Sonowal, R. Doley, B. Mondal, “Multiple protein-patterned surface plasmon resonance biochip for the detection of human immunoglobulin G”, J.Biophotonics., Jan 2023, doi: 10.1002/jbio.2022000263.
- iv. S. Giri, S. J. Taye, R. Shyam, B. Saikia, R. Jangid, **R. Yasmin**, R. Doley, “Recurrent Neurotoxicity in Naja kaouthia Envenomation: A Case Report from Assam, India”, Toxicon, Dec 2022, doi: 10.1016/j.toxicon.2022.106990.
- v. B. Khatun, M. Majumder, R. Mukhopadhyay, **R. Yasmin**, R. Doley, and T. K. Maji, “Effect of Curcumin-Hydroxypropyl-β-Cyclodextrin Complex and the Complex Loaded Gelatin Carrageenan Microparticles on the Various Chemical and Biological Properties,” J. Pharm. Innov., May 2021, doi: 10.1007/s12247-021-09559-0.
- vi. K. Borah, A. Singh, **R. Yasmin**, R. Doley, V. S. K. Mattaparthi, and S. Saha, “1α, 25-dihydroxy Vitamin D3 containing fractions of Catharanthus roseus leaf aqueous extract inhibit preadipocyte differentiation and induce lipolysis in 3T3-L1 cells,” BMC Complement. Altern. Med., vol. 19, no. 1, p. 338, Dec. 2019, doi: 10.1186/s12906-019-2754-7.

List of conferences

- i. **Rafika Yasmin**, Robin Doley, “Coagulopathy of *Daboia russelii* venom and search for anticoagulant proteins.” International Conference on Nextgen Genomics, Biology, Bioinformatics and Technologies Conference, 2019 (**Poster Presentation**)
- ii. **Rafika Yasmin**, Robin Doley, “Hide and seek between thrombin and Daboxin P.” National Seminar on Biology is Fascinating, 2022 (**Oral Presentation**)
- iii. **Rafika Yasmin**, Robin Doley, “*Daboia russelii* venom on platelet aggregation pathway.” National Webinar on Advances in Basic and Translational Research in Biology, 2022 (**Poster Presentation**)

Appendix

Permissions and approvals

Tezpur University Ethics Committee
Tezpur: 784028 : Assam

Communication of Decision of Tezpur University Ethics Committee (TUEC)

IEC No: DoRD/TUEC/PROP/2022/01

Protocol title: Identification and characterisation of anti-platelet proteins/peptides from Indian <i>Daboia russelli</i> venom and understanding its molecular mechanism		
Principal Investigator: Prof. R. Doley		
Name & Address of Institution: Tezpur University, Tezpur, Assam 784028		
<input checked="" type="checkbox"/> New review	<input type="checkbox"/> Revised review	<input type="checkbox"/> Expedited review
Date of review (D/M/Y): 29-09-2022		
Date of previous review, if revised application:		
Decision of the IEC/IRB:		
<input type="checkbox"/> Recommended	<input checked="" type="checkbox"/> Recommended with suggestions	
<input type="checkbox"/> Revision	<input type="checkbox"/> Rejected	
Suggestions/Reasons/Remarks: a) Blood will be collected under the supervision of concerned doctors. b) Initial approval is recommended for one year, with subsequent approval being subjected to satisfactory reports.		
Recommended for a period of: 1 year		

Please note

- Inform TUEC immediately in case of any adverse events and serious adverse events
- Inform TUEC in case of any change of study procedure, site and investigator
- This permission is only for period mentioned above. Annual report to be submitted to TUEC
- Members of TUEC have right to monitor the trial with prior intimation

Date: 21/03/2023

Signature of Chairperson (with seal)

TUEC

Chairperson
Tezpur University Ethics Committee

UNIVERSITY OF RAJSHAHI
INSTITUTE OF BIOLOGICAL SCIENCES

Rajshahi 6205, Bangladesh

Tel: (880-721) 750928, Cell. +880-01556312361, Fax + 880-721-711127, +880-721-750064

Email: director_ibsc@ru.ac.bd, yeasmin_bio@yahoo.com, <http://www.ibsc-ru.org>



Institutional Animal, Medical Ethics, Biosafety and Biosecurity Committee (IAMEBBC)
for Experimentations on Animal, Human, Microbes and Living Natural Sources

(Approved in the Resolution No. of the 71th meeting of the Board of Governors of the Institute of Biological Sciences and Resolution No. 57 of the 433th meeting of the Syndicate of the University of Rajshahi)

Memo No. 34 /320/IAMEBBC/IBSC

09 April, 2013

Certificate

This is to certify that the project title “CHARACTERIZATION OF SNAKE VENOM OF BANGLADESH AND ITS EFFECT ON DIFFERENT ORGANS OF MICE” Submitted by Dr.Md Abu Reza, Department of Genetic Engineering and Biotechnology, University of Rajshahi has been approved by the IAMEBBC in its resolution no. 6 of the 4rd meeting held on 9th April, 2013.


Name of Chairman: Prof. Dr. Tanzima Yeasmin



Signature with Date

9.4.13

Director
Institute of Biological Sciences
Rajshahi University



**UNIVERSITY OF RAJSHAHI
INSTITUTE OF BIOLOGICAL SCIENCES**

Rajshahi 6205, Bangladesh

Tel: +88-0721-750928, +88-0721711127, Cell. +88-01914254928, 01974254928; Fax +880-721-750064
E-mail: director_ibsc@ru.ac.bd/jakbiochem@ru.ac.bd http://www.dept.ru.ac.bd/ibsc



Dr. Jahan Ara Khanam
Professor & Director

Ref No: 390/IBSc

June 18, 2023

To whom it may concern

It is my pleasure to mention that Professor Dr. Md Abu Reza, the current Chairman of the Department of Genetic Engineering and Biotechnology, is working with snake and snake venom since 2010. He carried out his PhD and post-doctoral research from Professor Kini's Laboratory of the National University of Singapore and his title of PhD thesis was 'Parallel prothrombin activator systems in Australian Elapids: Their structure, gene organization, evolution and regulation of expression'. Upon his return to Bangladesh from Singapore he continued working with snake venomics and antivenomics. His group also developed the first ever database for snake venom (<http://snakebd.com>). He has significant contribution in the field of biomedical research more specifically in the field of snake venom research.

For pursuing research on snake venom and antivenom he has obtained permission from the University authority. His studies including collection/milking of venom (provided that the snakes to be handled according to the EU Directive 2010/63/EU for animals and to be released in the wild), neutralization experimentation on mice etc. are approved by the Institutional Animal, Medical Ethics, Biosafety and Biosecurity Committee (IAMEBBC) for Experimentations on animal, human, microbes and living nature sources (Memo no.-34/320/IAMEBBC/IBSc), Institute of Biological Sciences, University of Rajshahi, Bangladesh.

Jakhanam

(Dr. Jahan Ara Khanam)
Professor & Director
Institute of Biological Sciences
University of Rajshahi
Rajshahi, Bangladesh
And

Chairman of the Institutional Animal, Medical Ethics, Biosafety and Biosecurity Committee

ড. জাহান আরা খানম
প্রফেসর ও পরিচালক
ইনস্টিটিউট অব বায়োলজিক্যাল সায়েন্সেস
রাজশাহী বিশ্ববিদ্যালয়

18.06.23

DATE: 9.06.2012

CERTIFICATE

THIS IS TO CERTIFY THAT THIS SNAKE VENOM RELEASED ONLY FOR RESEARCH PURPOSE AND THIS PARCEL CONTAINS THE FOLLOWING SNAKE VENOMS.

1. COBRA SNAKE VENOM	1.000 gm
2. KRAIT SNAKE VENOM	1.000 gm
3. RUSSELL'S VIPER SNAKE VENOM	1.000 gm
4. SAW SCALED VIPER SNAKE VENOM	1.000 gm

SNAKE VENOMS WEIGHED BY

C.V. [Signature] 9.6.12

Special Officer
IRULA SNAKE CATCHERS ICS LTD.,

SNAKE VENOM WEIGHMENT INSPECTED

[Signature] 9.6.12

FOREST RANGE OFFICER,
WILDLIFE ENFORCEMENT RANGE,
CHENNAI - 32.

S. [Signature] 9.6.12

SNAKE VENOM PARCEL DESPATCH



TO

Dr. Dr. D.Velmurugan,
Professor,
University of Madras,
Dept. of Crystallography and Biophysics,
Guindy Campus,
Chennai - 25.